Clinical topic addressed by the source article: MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma
Key Mechanisms
The source describes SurVaxM as a cancer vaccine; it does not specify its mechanism.
Target Population
Population described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
Among 233 evaluable patients, median overall survival was 22.8 months with SurVaxM versus 20.3 months with placebo (HR 0.75; 95% CI 0.54–1.03; p=0.076, adjusted for MGMT and KPS stratification); the overall result did not reach the conventional statistical significance threshold.
In the prespecified subgroup aged 65 and under, median overall survival was 24.2 versus 20.2 months (HR 0.64; 95% CI 0.44–0.93; p=0.019, adjusted for MGMT and KPS stratification).
In patients aged 65 and under, progression-free survival favored SurVaxM (HR 0.64; p=0.018); 12-month progression-free survival was 44% versus 24%.
Among SurVaxM-treated patients aged 65 and under, approximately 42% were alive through 30 months or longer, compared with 18% in the placebo group.
SurVaxM was reported as well tolerated; Grade 3 or higher adverse-event rates were 48% with SurVaxM and 46% with placebo.
Guideline-Based Recommendations
Diagnosis
Management
SURVIVE evaluated SurVaxM in combination with standard of care for newly diagnosed glioblastoma; the article does not provide a clinical treatment recommendation.
Monitoring & Follow-up
The article states that continued follow-up and investigation are warranted for the reported long-term survival findings.
Risks
Common reported SurVaxM-associated events included injection-site reaction (48%), pain (41%), erythema (39%), pruritus (38%), swelling (29%), and influenza-like illness (13%).
Serious adverse-event rates were 25% with SurVaxM and 21% with placebo; adverse events led to treatment discontinuation in 4% of SurVaxM patients, with one discontinuation attributed to study treatment.
No treatment-related deaths were reported in either arm.
Patient & Prescribing Data
The trial included 233 evaluable patients with newly diagnosed glioblastoma. Patients aged 65 and under were a prespecified key subgroup.
SurVaxM was administered by subcutaneous injection and studied with standard of care. The article reports trial results, not prescribing instructions or an established regulatory approval.
Harold Burstein, MD, PhD, and Rachel Freedman, MD, MPH discuss the results of a new study looking at the impact of food access and poverty on patients with metastatic breast cancer. They also discuss the new Dana-Farber food pantry and patient navigators who help coordinate care.
